Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Transaction Details:
- Transaction Date: October 8, 2014
- Price per ADS: $45.253
- Transaction Type: Purchase of ADSs via dividend re-investment.
Material Changes
The filing details increases in personal holdings for the following individuals following the re-investment of dividends paid on October 2, 2014:
- Dr M M Slaoui: 1,596.680 ADSs
- Mrs D P Connelly: 977.321 ADSs
- Mr W C Louv: 316.608 ADSs
- Mr N Hirons: 172.356 ADSs
- Mr D E Troy: 989.503 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the total number of ADSs purchased by directors and PDMRs on October 8, 2014.
- Confirm the transaction price of $45.253 per ADS against market data for that date.
- Review the dividend payment date of October 2, 2014, to validate the re-investment timing.
- Check subsequent filings for any further changes in director holdings.